Aging Clinical and Experimental Research

, Volume 25, Supplement 1, pp 121–124 | Cite as

The bone anabolic therapy

  • A. Nardi
  • L. Ventura
  • L. Cozzi
  • G. Tonini
  • R. Zennaro
  • M. Celi
  • E. Ramazzina
Short Communication

Abstract

Teriparatide (TPTD), the amino-terminal parathyroid hormone recombinant peptide [PTH (1–34)], is a drug with a proven anabolic action on the bone, effective in preventing vertebral and non-vertebral fragility fractures. Recent publications have investigated in great detail the TPTD action on the cortical bone, highlighting the increased strength in the critical zone of the hip with high risk of fracture in osteoporotic patients Poole (PLoS ONE 6:e16190, 2011). In November 2002, TPTD was approved by the FDA for use in post-menopausal women and men with osteoporosis at high risk of fracture and in patients with glucocorticoid-induced osteoporosis and, since then, has been used to treat more than 1 million patients worldwide (J Bone Miner Res 27(12):2429–2437, 2012). The unchanged safety profile and the well-known mechanism of action of this drug have led doctors to explore the use of TPTD in other conditions such as delayed fracture healing, non-union, osteonecrosis of the jaw, etc. The positive reports that have resulted from these studies are helping to hypothesize a new perspective on the wider use of this drug, but warrant further clinical investigation to consolidate these results.

Keywords

Parathyroid hormone (PTH) Teriparatide (TPTD) Vertebral compression fractures (VCFs) 

References

  1. 1.
    Poole KES et al (2001) Targeted regeneration of bone in the osteoporotic human femur. PLoS ONE 6:e16190. |http://www.plosone.org. Accessed 1 January 2011 |
  2. 2.
    Andrews EB et al (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 27(12):2429–2437PubMedCrossRefGoogle Scholar
  3. 3.
    Borggrefe J, Graeff C, Nickelsen T et al (2010) Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS Study. J Bone Miner Res 25(3):472–481PubMedCrossRefGoogle Scholar
  4. 4.
    Graeff C, Chevalier Y, Charlebois M, Varga P et al (2009) Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res 24(10):1672–1680PubMedCrossRefGoogle Scholar
  5. 5.
    Nardi A, Tarantino U, Ventura L et al (2011) The domino effect: the rule of mechanical factors. Clin Case Miner Bone Metab 8(2):38–42Google Scholar
  6. 6.
    Bouxsein M, Chen P, Glass E, Kallmes D et al (2009) Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis: results from two randomized controlled trials. J Bone Joint Surg Am 91:1329–1338PubMedCrossRefGoogle Scholar
  7. 7.
    Alkhiary Y, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA (2005) Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 87:731–741. doi:10.2106/JBJS.D.02115 PubMedCrossRefGoogle Scholar
  8. 8.
    Kaback LA, Soung D, Naik A et al (2008) Teriparatide (1-34 human PTH) regulation of osterix during fracture repair. J Cell Biochem 105:219–226PubMedCrossRefGoogle Scholar
  9. 9.
    Aspenberg P, Genant HK, Johansson T et al (2010) Teriparatide for acceleration of fracture repair in humans: a prospective randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 25(2):404–414PubMedCrossRefGoogle Scholar
  10. 10.
    Pietrogrande L, Raimondo E (2013) Teriparatide in the treatment of non-unions: scientific and clinical evidences. Injury Int J Care Injured 44(Suppl 1):S54–S57. doi:10.1016/S0020-1383(13)70013-5
  11. 11.
    Corradini C, Macchia M, Malagoli E (2010) Enhanced healing of lateral femoral neck fractures in early women with teriparatide; new therapeutic horizon. Osteoporos Int 21:S177–S178Google Scholar
  12. 12.
    Lee YK, Ha YC, Koo NU (2012) Teriparatide, a non surgical solution for femoral nonunion? A report of three cases. Osteoporos Int 23(12):2897–2900PubMedCrossRefGoogle Scholar
  13. 13.
    Cherie YC, Roger MD et al (2013) Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 52:360–365CrossRefGoogle Scholar
  14. 14.
    Gomberg SJ, Wustrack R, Napoli N, Arnaud C et al (2011) Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 96(6):1627–1632PubMedCrossRefGoogle Scholar
  15. 15.
    Kwon Y-D et al (2012) Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int 23:2721–2725PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • A. Nardi
    • 1
  • L. Ventura
    • 2
  • L. Cozzi
    • 1
  • G. Tonini
    • 1
  • R. Zennaro
    • 3
  • M. Celi
    • 4
  • E. Ramazzina
    • 5
  1. 1.Osteoarticolar Pathology ServiceULSS 18RovigoItaly
  2. 2.Internal MedicineAzienda Ospedaliera Carlo PomaMantuaItaly
  3. 3.Internal MedicineULSS 19Porto ViroItaly
  4. 4.Department of Orthopaedics and TraumatologyUniversity of Rome “Tor Vergata”, “Policlinico Tor Vergata” FoundationRomeItaly
  5. 5.Internal MedicineULSS 18RovigoItaly

Personalised recommendations